Corbus drug shows promise as add-on therapy for cystic fibrosis

(Reuters) - An anti-inflammatory drug being developed by Corbus Pharmaceuticals Holdings as an add-on treatment for cystic fibrosis demonstrated promising safety and was well tolerated in a small midstage study, according to data released by the company on Thursday.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news